Compare Hims and Hers Health Inc (HIMS) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Schwab US Dividend Equity ETF — how do they compare? Hims and Hers Health Inc trades at $29.2 (market cap $6.55B), while Schwab US Dividend Equity ETF trades at $33.07 (market cap $110.56B). The key difference: Schwab US Dividend Equity ETF is far larger — about 16.9× Hims and Hers Health Inc's market cap, and Schwab US Dividend Equity ETF is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Schwab US Dividend Equity ETF for 62 Days on average.
| HIMS | SCHD | |
|---|---|---|
Market Cap | $6.55B | $110.56B |
Volume | 14,842,814 | 23,539,168 |
Sector | Health | Broad Market / Factor |
52-Week High | $62.76 | $35.21 |
52-Week Low | $14.52 | $26.44 |
Typical Hold Time | 21 Days | 62 Days |
Enterprise Value | $7.25B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.
The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.
SCHD trades at $32.65, down 0.61% with a bearish technical signal from moving averages. Recent news highlights its strong 2026 performance against the S&P 500 and a recent dividend declaration. The ETF's defensive dividend strategy faces pressure from rising interest rates, contributing to recent price weakness from August highs near $35.
The outlook balances income growth potential against interest rate sensitivity. Near-term support at $32 provides a key level to watch, while the dividend-focused approach offers stability for long-term investors despite current technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
